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1. Introduction 
Endometrial cancers are the most common malignancies of the female genital tract in the 
United States, with 42,160 new cases diagnosed and 7780 cancer-associated deaths in 2009 
(Jemal, Siegel et al. 2009). The histopathological classifications of endometrial cancers are 
numerous, but in 1983, two broad clinico-pathologic categories of endometrial carcinomas 
were delineated (Bokhman 1983). This conceptual classification has largely been based on 
light microscopic appearance, clinical behavior and epidemiology, and had been 
subsequently supported by molecular-cytogenetic data, which has facilitated the acceptance 
of the so-called dualistic model of endometrial carcinogenesis(Deligdisch and Holinka 1987; 
Lax and Kurman 1997; Sherman 2000; Matias-Guiu, Catasus et al. 2001; Lax 2004; Liu 2007), 
a modified and more comprehensive comparison of both types is illustrated in Table 1. 
According to that model, the first and the most common type of endometrial carcinoma is 
called Type I endometrial cancer. These Type I cancers, of which the pathologic prototype is 
endometrioid carcinoma, represent at least 80% of newly diagnosed cases of endometrial 
cancer. The much less common mucinous carcinomas are also generally classified as a Type 
I cancer. Overall, they occur in comparatively younger age group (40-50 years)(Deligdisch 
and Holinka 1987; Lax and Kurman 1997; Sherman 2000; Matias-Guiu, Catasus et al. 2001; 
Lax 2004; Liu 2007). The tumor cells frequently express estrogen and progesterone receptors 
(Demopoulos, Mesia et al. 1999; Lax 2004), and their evolution appears to be driven by 
unopposed estrogen stimulation from either endogenous (e.g. ovarian estrogen-producing 
tumors) and/or exogenous sources (e.g. hormonal therapy)(Ettinger, Golditch et al. 1988; 
Potischman, Hoover et al. 1996; Demopoulos, Mesia et al. 1999). These tumors, therefore, 
mostly arise in a background of endometrial glandular hyperplasia(Lax 2004; Liu 2007). Type 
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I endometrial cancers have a relatively favorable prognostic profile compared to type II 
endometrial cancer  (Creasman, Odicino et al. 2003). Several kinds of genetic alterations had 
been detected in Type 1 endometrial cancers, including PTEN inactivation(Tashiro, Blazes et 
al. 1997; Mutter, Ince et al. 2001), beta-catenin (CTNNB1) mutations (Konopka, Janiec-
Jankowska et al. 2007), and to a lesser degree, microsatellite instability (related to 
inactivation of the MLH1 gene) (Esteller, Levine et al. 1998), and activational mutations of 
the K-ras gene (Velasco, Bussaglia et al. 2006). 
 
Parameters Type I Type II 
Incidence  80% 15% 
Peak Age 50-60 60-70 
Obesity Common Uncommon 
Estrogen stimuli Common Uncommon 
Precancer EIN (classic) 
EmGD (serous type &  
clear cell type) 
Latent Precancer PTEN null glands P53 signature glands 
Progression Slow Rapid 
Histology Endometrioid, mucinous 
Serous, Clear cell, and 
Carcinosarcoma 
Genetic changes PTEN, MSI p53, BRCA, 1pDel 
Familial HNPCC Unknown 
Prognosis Good Poor 
Table 1. Dualistic model of endometrial cancer as modified by Zheng et al  (Zheng, Xiang et 
al. 2011).  
Type II endometrial cancer in the dualistic model are significantly less common than their 
Type I counterparts, and represent only10- 15% of cases. The pathologic prototype of this 
category is the endometrial serous carcinoma (ESC) [previously termed uterine papillary 
serous carcinoma (UPSC)]. Type II endometrial cancer typically occurs in an older age group 
(60-70 years) (Lax and Kurman 1997; Sherman 2000; Matias-Guiu, Catasus et al. 2001). They 
frequently arise in a background of inactive or resting endometrium(Lax and Kurman 1997; 
Sherman 2000; Matias-Guiu, Catasus et al. 2001), display a low frequency of expression of 
hormonal receptors, are not associated with the estrogen-associated clinical factors (such as 
obesity)and generally are not thought to be directly influenced  by hormones (Sasano, 
Comerford et al. 1990; Lax, Pizer et al. 1998; Demopoulos, Mesia et al. 1999; Lax 2004; Shang 
2006). Definitive risk factors for type II endometrial cancer are still unclear, however. In one 
recent study, we found that women 55 years of age or  under with a personal history of 
breast cancer, had an increased risk of ESC as compared with controls (Liang, Pearl et al. 
2010), and an earlier study by Chan et al came to comparable conclusions 2006 (Chan, 
Manuel et al. 2006). These Type II cancers, most notably ESC, also exhibit frequent mutation 
and overexpression of the p53 (Sherman, Bur et al. 1995; Nordstrom, Strang et al. 1996) and 
HER2/neu (Rolitsky, Theil et al. 1999) genes and proteins, respectively. They also show 
alterations of intercellular adhesion molecules like E-cadherin (Holcomb, Delatorre et al. 
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2002; Mell, Meyer et al. 2004) and claudin(Santin, Bellone et al. 2007; Konecny, Agarwal et al. 
2008), and display over-expression of p16 (Chiesa-Vottero, Malpica et al. 2007; 
Yemelyanova, Ji et al. 2009) and IMP-3(Reid-Nicholson, Iyengar et al. 2006; Zheng, Yi et al. 
2008). Overall, type II endometrial cancer have a relatively poor prognosis independent of 
other factors, and a higher mortality rate in comparison to type I cancers(Lauchlan 1981; 
Eifel, Ross et al. 1983; Sherman, Bitterman et al. 1992). This dualistic model has provided a 
valuable academic framework for the subsequent studies of myriad aspects of endometrial 
carcinogenesis and progression and a conceptual basis for the differential deployment of 
histotype-specific treatment modalities. 
1.1 Endometrial Intraepithelial neoplastic lesions: The nomenclature dilemma 
Endometrial cancers, especially type II endometrial cancer, are a significant cause of morbidity 
and mortality in women (Jemal, Siegel et al. 2009). This has prompted the long-standing search 
for optimal approaches for their prevention; one aspect of prevention is the early recognition 
of occult precursor lesions or precancers (Berman, Albores-Saavedra et al. 2006), along with the 
administration of therapeutic interventions prior to the development of overt malignancy. To 
establish any lesion as a precursor lesion or a precancer to one neoplasm, the putative lesion 
should meet some basic criteria that defines a precancer, as recognized by participants at a 
consensus conference on the subject sponsored by the National Cancer Institute in 2006 
(Berman, Albores-Saavedra et al. 2006). This definition modifies and generalizes a definition 
initially proposed for endometrial intraepithelial neoplasia  (Mutter 2000; Mutter, Baak et al. 
2000; Mutter, Ince et al. 2001; Mutter 2002; Hecht and Mutter 2006; Mutter, Zaino et al. 2007) . 
The following five defining criteria must all be met: “(1) Evidence exists that the precancer is 
associated with an increased risk of cancer. (2) When a precancer progresses to cancer, the 
resulting cancer arises from cells within the precancer. (3) A precancer is different from the 
normal tissue from which it arises. (4) A precancer is different from the cancer into which it 
develops, although it has some, but not all, of the molecular and phenotypic properties that 
characterize the cancer. (5) There is a method by which the precancer can be diagnosed”. In the  
last two decades, there have been significant advances made  in the study of the precursors of 
Type I endometrial cancer, and this precancerous lesion is currently considered as endometrial 
atypical hyperplasia in the WHO classification system (that is still the most frequently used by 
pathologists) and the “endometrial intraepithelial neoplasia (EIN)” system that was originally 
proposed by Mutter et al  (Mutter 2000; Mutter, Baak et al. 2000; Mutter, Ince et al. 2001; 
Mutter 2002; Hecht and Mutter 2006; Mutter, Zaino et al. 2007). On the other hand, studies of 
Type II endometrial cancer precursors have been relatively limited. The prototype of Type II 
endometrial cancer, which is ESC, usually arises in a background of atrophic or resting 
endometrium. This is in contrast to Type I endometrial cancer, which generally have a 
hyperplastic (or at least non-atrophic) background and show a strong relation to high estrogen 
levels. For this and a variety of other reasons, the precancers of type I endometrial cancer are 
highly unlikely to constitute the precancer lesions for Type II endometrial cancer. Numerous 
lines of evidence developed during the last decade point toward a newly recognized lesion 
called “endometrial glandular dysplasia (EmGD)” as the actual precursor of Type II cancers, 
including serous and clear cell types (Zheng, Liang et al. 2004). These lines of evidence include 
pathologic, genetic as well as clinical factors. Accordingly, the precancer of type I endometrial 
cancer and type II endometrial cancer are two distinct entities at the morphologic and molecular 
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levels and are not related to each other. In this chapter, we explore the current state of 
knowledge on all types of precancerous lesions of the endometrium, based on our 
interpretation and modification of the dualistic model of endometrial carcinogenesis. Clinical 
and pathological experience in endometrial carcinogenesis had shown a significant impact of 
histologic subtype (endometrioid, serous, clear cell etc) on overall prognosis and survival. 
Considering the multiple conflicting nomenclatures that existed in studies of endometrial 
carcinogenesis, which lead to the inappropriate inclusion of some entities as ‘precancers’ (as 
discussed in following sections),we plan to propose a unified terminology and classification 
scheme for the precancerous lesions in the endometrium, which will be biology-based and 
clinically oriented for better patient care. Accordingly, the discussion of intraepithelial 
neoplastic lesions of the endometrium would embrace the precancer of type I endometrial cancer, 
which we will refer to as endometrioid EIN; as well as the precancers of type II endometrial 
cancer, that is, serous EmGD and clear cell EmGD, which will be referred to as serous EIN and 
clear cell EIN respectively. As summarized in Figure 1. 
EIN
Serous EmGD
Serous typeEndometrioid (classic) type Clear cell type
Type I endometrial cancer
(EEC, mucinous etc)
Clear cell EmGD
Type IIType I
(Also include mucinous type)
ESC ECCC
Type II endometrial cancer
(ESC, ECCC, CS etc)
Zheng et al, 2011  
Fig. 1. A proposed unified model of endometrial carcinogenesis. Endometrial intraepithelial 
neoplasia (EIN) encompass a broad spectrum of morphologically and biologically distinct 
entities, categorized as type I, referring to the classic EIN lesion described by Mutter, and type 
II that include serous EmGD and clear cell EmGD as precancers of type II endometrial cancer. 
2. Precancers of type I endometrial cancers 
2.1 Historical backgrounds  
In the past, Type I endometrial cancer was thought to be preceded by pan-endometrial 
hormonally induced changes referred to as endometrial hyperplasia. The term endometrial 
hyperplasia encompasses a broad spectrum of polyclonal proliferations that result from a 
physiological response of the endometrium to an abnormal estrogenic stimulus. The 
magnitude of such proliferations, reflects the quantity and duration of unopposed estrogen 
exposure (Trial 1996; Mutter, Zaino et al. 2007), resulting in architecturally variable glands 
covering a surface area that is equal or exceeds that of the stroma (i.e. gland-stroma ratio 
more than 1:1). The most widely observed histological features include irregular 
architectural remodeling of endometrial glands in functionalis layer, vascular thrombi, and 
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stromal breakdown. A critical feature of benign hyperplasia is that no significant cytological 
changes are seen between the hyperplastic glands and the surrounding glands (Mutter, 
Zaino et al. 2007). Benign endometrial hyperplasia is most frequent around the time of the 
menopause, due to alterations of the normal cycle of sequentially regulated estrogen and 
progesterone. It may also occur following anovulatory cycles for the same reason. The most 
common symptoms of hyperplasia are prolonged or excessive bleeding at intervals that are 
initially longer than normal. Microinfarcts and estrogen withdrawal are responsible for 
symptomatic bleeding (Song, Rutherford et al. 2002; Ferenczy 2003). Other patients may 
complain of intermittent spotting, commonly attributed to patchy stromal breakdown 
secondary to estrogen-induced microthrombi. A rapid decline in the prolonged estrogen 
stimulation causes massive apoptosis of the endometrial glands and stroma resulting in 
heavy shedding. Occasionally, the decrease in estrogen levels is sufficiently gradual that 
generalized apoptosis and shedding fail to take place as regular menstruation. 
The World Health Organization (WHO) 1994 classification system subdivided endometrial 
hyperplasia according to architectural complexity and cytological atypia into 4 subgroups: 
simple, simple hyperplasia without atypia, complex, and atypical complex hyperplasia 
(Scully RE 1994), as illustrated in Figure 2. The WHO 1994 endometrial hyperplasia schema 
confines most precancers of type I endometrial cancer in the atypical hyperplasia subgroup, 
but in the opinion of many pathologists and investigators, there are several problems 
associated with this classification. First, this classification system is poorly reproducible 
among pathologists (Hunter, Tritz et al. 1994; Skov, Broholm et al. 1997; Zaino 2000). 
Second, this system is missing diagnostic elements that have only become clear in recent 
years. Of these elements, the localizing topographic distribution of a clonally expanding 
precancer and the need to establish size thresholds for diagnosis. Third, it is a purely 
morphology-based system without any supporting molecular and morphometric studies 
that precisely quantifies diagnostic architectural changes. The search for an alternative 
classification system for endometrial carcinomas had lead to the introduction of the 
Endometrial Intraepithelial Neoplasia (EIN) entity. 
 
Fig. 2. A: simple hyperplasia, B: simple hyperplasia without atypia, C: complex hyperplasia,  
D: atypical complex hyperplasia. Arrows indicate residual uninvolved glands. Inset: 
magnified area with arrow, a hyperplastic gland shows atypical distinct morphology 
compared to adjacent resting endometrial gland (RE). 
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2.2 EIN: Mutter’s model for type I endometrial cancer 
The concept of EIN and the diagnostic schema was introduced by Mutter and the Endometrial 
Collaborative Group in 2000 (Mutter 2000); and later launched at Brigham and Women’s 
Hospital in 2002  (Mutter 2002; Hecht, Ince et al. 2005), to replace the older hyperplasia-based 
nomenclature, the currently used terminology by WHO 1994 classification system(Scully RE 
1994), which implies endometrial hyperplasia as the precancerous lesion of type I cancers. This 
concept was the result of cautious correlation of genetically ascertained pre-malignant lesions 
with histopathologic feature and clinical outcomes. A better vision of the carcinogenesis of type 
I endometrial cancer was achievable with the advent of polymerase chain reaction–based clonal 
assays and relevant biomarkers that facilitated a molecular, rather than purely morphologic 
approach to precancer diagnosis. The molecular entity of EIN is thought to be a clinically 
pertinent lesion that can be reproducibly diagnosed by pathologists and targeted for 
therapeutic intervention. According to this model, the premalignant lesions are referred to as 
EIN to distinguish them from the diffuse estrogen associated changes of benign endometrial 
hyperplasia. EIN is a” histologically recognizable localized lesion composed of a clonal 
proliferation of glands and that usually carry one or several of the genetic abnormalities 
associated with endometrioid carcinoma” (Mutter, Boynton et al. 1996; Mutter, Baak et al. 
2000) . This model had been supported by molecular and morphometric studies. First, the 
monoclonality of EIN lesions was proven utilizing nonrandom X-chromosome inactivation 
(HUMARA assay) and clonal propagation of altered microsatellites (Mutter, Chaponot et al. 
1995; Jovanovic, Boynton et al. 1996). Second, the identification of lineage continuity with 
subsequent carcinomas that occur in the same patient, fulfilling a vital standard for molecular 
definition of precancers(Mutter, Baak et al. 2000). Third, the application of computer based 
morphometry has been successful at further improving diagnostic reproducibility of precursor 
diagnosis, and have a better correlation between morphologic features and patient actual 
clinical outcome(Baak, Nauta et al. 1988; Baak, Wisse-Brekelmans et al. 1992). The applied 
morphometric measures were combined into a threshold D-score (detailed below). In 2005, a 
meta-analysis study of the cumulative outcome prediction experience of the D-score (Baak, 
Mutter et al. 2005), showed that patients with a D-score less than 1 have an overall 89-fold 
increased cancer risk than those with D-score more than 1. Even if one excludes concurrent 
cancers, those diagnosed within 12 months of EIN, cancer risk over the next two decades is 45-
fold that of controls. Comparison of the WHO 94 and the EIN systems, with correlation of the 
clinical outcome reveals a degree of overlapping. Mutter et al  (Hecht, Ince et al. 2005) had 
found that, for the simple non-atypical hyperplasia, only a minimal risk for endometrial cancer 
is believed to be present (only 5% are re-diagnosed as EIN upon review). Complex atypical 
hyperplasia has the highest risk of cancer and 80% of cases are rediagnosed as EIN (the 
greatest overlap). Therefore, majority of EIN lesions are actually equivalent to most of the 
WHO atypical complex hyperplasia category. Detailed relationship is illustrated in Figure 3. 
2.2.1 Diagnostic features of EIN 
As defined by Mutter et al, EIN is ‘the premalignant clone of an endometrial lesion that is 
characteristically offset from the background endometrium by its altered cytology and 
crowded architecture’. This definition implies the use of an internal control for cytologic 
atypia, which is the benign resting endometrium, combined with the distinctive topography 
of a clonal process. The average age of women with EIN is 52 years (Baak, Mutter et al. 
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2005), almost a decade younger than the average age for cases of endometrioid endometrial 
carcinoma in patients with concurrent endometrioid carcinoma (Baak, Mutter et al. 2005; 
Hecht and Mutter 2006), and when those patients are excluded, the average time following 
EIN detection to carcinoma diagnosis is 4 years(Baak, Mutter et al. 2005). The clinical 
significance of EIN lesions is that they represent a long-term cancer risk that is 45-fold 
greater than that of their benign endometrial hyperplasia counterparts (Hecht and Mutter 
2006; Mutter, Zaino et al. 2007). This distinctive clinical profile, is further supported by 
morphometric measures, summed up under the term D-score, which includes the volume 
percent stroma (a measure of gland crowding); standard deviation of the shortest nuclear 
axis (a measure of nuclear pleomorphism); and gland outer surface density (a measure of 
branching and folding). The morphometric techniques were effective at discriminating those 
endometrial lesions which progress to adenocarcinoma from those that do not (Baak, Nauta 
et al. 1988). However, we would like to point out that the morphometric techniques are so 
far mainly limited to research applications rather than in general practice. 
 
Fig. 3. Mutter’s diagram (Hecht, Ince et al. 2005) for overlaps between WHO and EIN 
classification systems. 
Based on the model of EIN, 5 strict morphologic features are applied, and all 5 criteria must 
be met in each case to maintain a high level of diagnostic specificity and predictive value. 
The diagnostic criteria are summarized in Table 2. 
Architecture 
A feature that makes EIN lesions readily visible under low magnification. Area of glands 
exceeds that of stroma, thus, the surface area of glands (combined epithelium and lumen) is 
greater than that of the stroma that contains them, and the tissue proportion occupied by 
stroma is less than 50%. However, this ratio is also used as a diagnostic feature for benign 
endometrial hyperplasias. To overcome the potential source of diagnostic confusion, strict 
search for the other 4 criteria is critical to confirm the lesion in question is EIN and not a 
focus of endometrial hyperplasia. Another important point to mention is the condition of 
the endometrial stroma within the area of question.  
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EIN feature Definitions  
Architecture  Area of glands exceeds that of stroma (glands/stroma > 1). Lesion 
composed of individual glands, which may branch slightly and vary in 
shape. 
Cytology  Nuclear and/or cytoplasmic features of epithelial cells differ between 
glands with abnormal architecture and those with normal background.  
May include change in nuclear polarity, nuclear pleomorphism, or altered 
cytoplasmic differentiation state.  
Highly abnormal cytology if no normal comparison glands are present 
Size  Maximum linear dimension exceeds 1 mm 
Exclude 
benign 
mimics 
Benign conditions with overlapping criteria :disordered proliferative, 
basalis, secretory, polyps, repair, etc. 
Exclude 
cancer 
Carcinoma if mazelike glands, solid areas, or 
significant cribriform growth. 
Table 2. Essential diagnostic criteria of EIN as outlined by Mutter et al  
(Mutter, Zaino et al. 2007). 
Cytologic Changes 
This must be judged individually in each case using the native background endometrium as 
the internal control (Figure 4 A). No unified diagnostic cytologic features are settled for EIN, 
this is due to several factors. First, the variability of the cytological characteristics of the 
endometrial glandular epithelium among specimens, according to fixation, processing, and 
staining. Second, this inconsistency also depends largely on the fluctuating hormonal 
environment. Third, not all EIN lesions maintain endometrioid differentiation (Mutter, 
Zaino et al. 2007), and commonly acquire metaplastic changes, including mucinous, 
  
Fig. 4. Diagnostic features to look for in EIN lesions. EIN glands are cytologically distinct 
from the surrounding normal endometrial glands (A, 200x). The lesion should be at least 
1mm in dimension (B, 40x). 
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squamous morular, tubal, eosinophilic, or micropapillary changes. The practicing 
pathologist should be careful, however, not to confuse the relatively mild cytologic atypia of 
EIN lesions with the striking atypia with possibly hobnailed nuclei seen in the precancer of 
type II endometrial cancer (serous EmGD and clear cell EmGD). 
Size 
The lesion must be at least 1 mm in dimension in a single tissue fragment (Figure 4B). This 
“golden” number needs to be present in only one dimension of the lesion. Separate foci cannot 
be added to achieve this minimum size, it must be met in a single focus(Mutter, Zaino et al. 
2007). The reason why a size parameter is needed in such a lesion, is probably to confer 
reproducibility and predictive value in pathological and the clinical sides, respectively. It may 
also significantly reduce the risk of EIN overdiagnosis in minute randomly detected foci of 
glandular crowding. One problem of the size limit is that about 20% of EIN lesions are diffuse 
and non-localized by the time they are detected(Mutter, Zaino et al. 2007), such a diagnostic 
difficulty might be overcome by largely depending on the other diagnostic criteria. Lesions 
that have most of the diagnostic criteria for EIN but are <1mm in dimension are still of 
unknown clinical significance, but are thought to be a good indication for subsequent follow-
up endometrial sampling. However, in a recent study by Huang et al(Huang, Mutter et al. 
2010), 71 579 consecutive gynecological pathology reports were retrieved, of which, 206 (0.3%) 
cases with ‘gland crowding’ were identified, in which 69% (143/206) had follow-up sampling. 
Of these, 33 (23%) had an outcome diagnosis of EIN (27 cases; 19%) or carcinoma (6 cases; 4%). 
Included were 18 cases (55%) diagnosed within the first year and presumed concurrent, and 
an additional 15 (45%) discovered after 1 year and interpreted as a later phase of disease or 
new events (Huang, Mutter et al. 2010). The authors suggested that such “gland crowding” is 
significant and deserves mention in pathologic reports. 
Exclusion of benign mimics 
Many innocent conditions are frequently encountered during routine examination of 
endometrial specimens, and these may be the source of diagnosticdifficulty in the exclusion of 
a potential EIN lesion. These may include (but are not limited to) artifactually pushed together 
or telescoped endometrial glands; or crowding related to the late secretory endometrium, in 
which the gland density may be very high in the deep functionalis where predecidual change 
is minimal (Figure 5A). Some portions of specialized but otherwise normal endometrium such 
as lower uterine segment or uterine basalis may also cause confusion, these are usually 
identified by their fibrous stromal context and quiescent epithelium. Another more serious 
misinterpretation comes when dealing with endometria under the influence of estrogen 
withdrawal, either during the normal menstruation or as a result of hormonal imbalances, the 
resulting microscopic picture is collapsed glands and stromal condensation. This frequently 
results in irregular glands lacking much stromal separation, giving an EIN-like picture (Figure 
5B). Overall, the most commonly overdiagnosed lesions as EIN are probably endometrial 
polyps (as well as with endometrial hyperplasia), yet, their characteristic altered stroma and 
thick vessels, are readily distinct from the stromal features of EIN. 
Exclusion of cancer 
EIN lesions are composed of clusters of individually recognizable glands, whereas 
endometroid carcinoma show  more complex growth patterns not seen in EIN, such as solid, 
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cribriform, or complex interlacing mazelike growth (Figure 6A &B). The presence of 
myoinvasion is also diagnostic of carcinoma (Figure 6C), but this is better applied to 
hysterectomy specimens where intact myometrial wall is present. Overly malignant 
cytologic features beyond that seen in EIN are also present (Figure 4D). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Benign mimics of EIN. Late secretory endometrium displays prominent tortuous 
glands and crowding (A, 40x). Breakdown changes with artificially crowded irregular 
glands due to stromal collapse (B, 100x).  
In our current proposal for a unified and simplified nomenclature for the precancers of 
endometrial cancers, we prefer to refer to this classic EIN entity described above as 
‘endometrioid EIN’. 
2.2.2 Differential diagnosis  
Many of the important mimics of EIN lesions have been discussed in the preceding sections 
(exclusion of benign mimics and exclusion of cancer). Another differential diagnostic 
consideration that is worth mention is the precancer of type II endometrial cancer (in our 
opinion, serous EmGD and clear cell EmGD). Unlike type II endometrial precancers, 
endometrioid EIN cells lack high-grade cytologic features, including hobnail nuclei. Also 
endometrioid EIN usually has a high-level estrogen stimulation, yet this is not the usual 
scenario in serous or clear cell EIN. Immunohistochemical studies with p53 and IMP3 are 
useful as these markers are positive in serous EmGD but not in endometrioid EIN.  
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Fig. 6. Features of endometrioid carcinoma, and not EIN. Cribriform glands (A,100x), solid 
growth pattern (B, 40x), presence of muscular invasion (C, 20x), or frankly malignant 
cytologic features (D, 200x).  
2.3 Molecular insights 
2.3.1 Type I endometrial cancer and sex hormones 
The normal endometrial epithelial cells are highly responsive to sex hormones, namely, 
estrogens and progesterone; and the morphology of the endometrium at any point is the 
sum of these responses and interactions. Consequently, the risk for type I endometrial cancer is 
significantly affected by the reciprocal and “opposing”actions of estrogens and 
progesterones, and is a dynamic process that depends on temporal changes in tissue 
responsiveness. The same is true for the resultant cancer in which the neoplastic cells retain 
this feature of hormone-responsiveness. Studies of the expression profiling of type 1 
endometrial cancer cells had shown resemblance to the expression profile seen in estrogen-
driven proliferative endometrium, it also lacks expression of some genes induced by 
progestins (Hecht and Mutter 2006). 
On one hand, estrogens are promoters of cell proliferation and inhibitors of apoptosis, the 
effect of which is a manifestation of a complex downstream sequence of transcription 
changes that may involve modulation of tumor suppressor genes. These changes may 
include alterations in PTEN, PAX2, and HOXB13 among others. PTEN expression in normal 
endometrial glands is greatly elevated by estrogens and reduced by progestins during 
hormonal fluctuations of the normal menstrual cycle(Mutter, Lin et al. 2000). As promoters 
of proliferative activity, estrogens may also increase probability of arbitrary 
mutations(Cairns 1998), as well as increase the rate of mutagenesis through free radical 
formation (Burcham 1999), although the magnitude of this effect is minimal. Overall, large-
scale population studies had shown that women exposed to “unopposed” estrogens have 2 
to 10 folds increased risk for type I endometrial cancer, and this wide range is influenced by 
the dose and duration of exposure (Parazzini, La Vecchia et al. 1991; Potischman, Hoover et 
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al. 1996; Trial 1996; Zeleniuch-Jacquotte, Akhmedkhanov et al. 2001). Moreover, EIN lesions 
are thought  to attain high levels of nuclear estrogen receptors (Mutter, Ince et al. 2001), 
thus, estrogens may also act as growth positive selectors of the previously mutated cells, 
allowing their clonal expansion. 
On the other hand, progestins have the ability to “oppose” the biologic effects of coexisting 
estrogens through down-regulation of the estrogen receptor itself in the endometrial 
epithelial cells. This is actually the basis of combined estrogen/progesterone therapies, in 
which the net effect is dominated by the progestin component. It is also known to be the 
reason behind the protective influence of combined oral contraceptives, women who uses 
these drugs are said to have 0.5 to 0.7 fold risk of type I endometrial cancer compared to 
controls (Grimes and Economy 1995; Weiderpass, Adami et al. 1999). Other protective 
effects of circulating progestins are due to downregulation of proliferative promoters like 
PTEN, thus it was found that PTEN mutant clones have a tendency to involute under the 
influence of progestins (Zheng, Baker et al. 2004). The anti-cancer role of progestins is 
further mediated by induction of apoptosis through the increased expression of Bcl-2 and 
BAX (Vereide, Kaino et al. 2005).  
2.3.2 Molecular alterations in type I endometrial cancer and endometrioid EIN 
Type I endometrial cancer demonstrate large numbers of genetic changes in which the sequential 
order of mutation, and the final combination of defects differ considerably between individual 
examples (Hecht and Mutter 2006). Common genetic changes in endometrioid carcinoma 
include, but are not limited to, microsatellite instability (MSI) (Risinger, Berchuck et al. 1993; 
Duggan, Felix et al. 1994; Kobayashi, Matsushima et al. 1996; Mutter, Boynton et al. 1996; 
Catasus, Bussaglia et al. 2004), or specific mutation of PTEN (Risinger, Hayes et al. 1997; 
Tashiro, Blazes et al. 1997; Levine, Cargile et al. 1998; Maxwell, Risinger et al. 1998; Gurin, 
Federici et al. 1999; Mutter, Lin et al. 2000), K-ras (Enomoto, Inoue et al. 1991; Fujimoto, 
Shimizu et al. 1993; Duggan, Felix et al. 1994; Sakamoto, Murase et al. 1998; Mutter, Wada et al. 
1999; Swisher, Peiffer-Schneider et al. 1999; Lax, Kendall et al. 2000; Lagarda, Catasus et al. 
2001), and β-catenin genes (Kobayashi, Matsushima et al. 1996; Fukuchi, Sakamoto et al. 1998; 
Mirabelli-Primdahl, Gryfe et al. 1999; Schlosshauer, Pirog et al. 2000). As previously described, 
it is the clonal origin of EIN that supports its definition as a precancer. Moreover, studies by 
Mutter et al gave considerable evidence that comparison of the type and magnitude of 
genomic damage between endometrioid EIN and type I endometrial cancer (Mutter, Boynton et 
al. 1996; Esteller, Catasus et al. 1999; Mutter, Baak et al. 2000; Mutter, Lin et al. 2000), indicates 
a greater cumulative mutational burden in the later , a feature considered one milestone in the 
definition of precancer (Berman, Albores-Saavedra et al. 2006). Below is a discussion of the 
most commonly encountered molecular alterations. 
PTEN 
Inactivation of the PTEN tumor-suppressor gene (formerly known as MMAC1) is the most 
common genetic defect in endometrioid carcinoma and is seen in up to 83% of tumors that 
are preceded by a histologically discrete premalignant phase (Mutter, Lin et al. 2000). It acts 
as tumor suppressor genes because their proteins may counteract the effect of the proteins 
encoded by the protein kinase group of protooncogenes (Matias-Guiu, Catasus et al. 2001). 
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The most frequently encountered alterations of PTEN in endometrial cancers are LOH at 
chromosome 10q23 (40% of EC) (Jones, Koi et al. 1994; Peiffer, Herzog et al. 1995); and 
somatic mutation, which are almost exclusively found in type I endometrial cancer (37 to 61%) 
(Kong, Suzuki et al. 1997; Tashiro, Blazes et al. 1997; Maxwell, Risinger et al. 1998; Bussaglia, 
del Rio et al. 2000). A number of investigators have found a concordance between 
microsatellite instability status and PTEN mutations; the mutations occur in 60% to 86% of 
MSI (+) endometrioid carcinoma, but in only 24% to 35% of the MSI (-) tumors (Matias-
Guiu, Catasus et al. 2001). Such results have led to the assumption that PTEN could be a 
likely target for mutations in MSI (+) EC. PTEN inactivation was detected frequently in EIN 
lesions (63% of cases) (Mutter, Ince et al. 2001). However, the routine application of PTEN as 
an informative marker of premalignant lesions is still questionable due to several facts. First, 
PTEN mutations have been detected in endometrial hyperplasia with and without atypia 
(19% and 21% respectively) (Levine, Cargile et al. 1998; Maxwell, Risinger et al. 1998; 
Bussaglia, del Rio et al. 2000). Second, the lack of PTEN inactivation in about one third of 
studied EIN lesions(Mutter, Zaino et al. 2007). And finally, the finding of somatic 
inactivation of PTEN in scattered benign endometrial gland in 43% of cases.(Mutter, Ince et 
al. 2001) 
B-catenin (CTNNB1) 
Gain of function mutations in exon 3 of CTNNB1 gene at 3p21 are seen in 25% to 38% of type 
I endometrial cancers (Fukuchi, Sakamoto et al. 1998; Schlosshauer, Pirog et al. 2000). B-
catenin is a component of the E-cadherin-catenin unit essential for cell differentiation and 
maintenance of normal tissue architecture, and plays an important role in signal 
transduction (Hecht and Mutter 2006). B-catenin mutation may represent a pathway to 
endometrial carcinogenesis characterized by squamous differentiation and independent of 
PTEN (Su, Vogelstein et al. 1993). B-catenin expression change is usually a diffuse process 
seen in all tumor cells, and is present in some premalignant lesions (Hecht and Mutter 2006). 
This suggests that B-catenin mutation is an early step of endometrial tumorigenesis that is 
clonally represented in all tumor cells (Matias-Guiu, Catasus et al. 2001; Saegusa, 
Hashimura et al. 2001; Hecht and Mutter 2006). Furthermore, B-catenin might regulate the 
expression of the matrix metalloprotease-7, which would have a role in the establishment of 
the microenvironment necessary for the initiation and maintenance of growth of the 
primary tumors and their metastasis. (Brabletz, Jung et al. 1999). Further studies are needed 
to explore the role of B-catenin in type I endometrial cancer carcinogenesis. 
K-RAS 
K-RAS mutations have been identified in 10% to 30% of type I endometrial cancer (Sasaki, 
Nishii et al. 1993; Swisher, Peiffer-Schneider et al. 1999; Lax, Kendall et al. 2000). There is a 
higher frequency of K-ras mutations in cancers with microsatellite instability (MSI), and 
many of these are characterized by methylation related GC3AT transitions(Lagarda, Catasus 
et al. 2001). Several investigators had previously found associations between k-RAS 
mutations and the presence of coexistent endometrial hyperplasia, (Tsuda, Jiko et al. 1995) 
lymph node metastases, and clinical outcome in postmenopausal patients over 60 years of 
age (Ito, Watanabe et al. 1996). In addition, some investigators have reported an almost 
complete absence of k-RAS mutations in serous and clear cell carcinomas of the 
endometrium (Caduff, Johnston et al. 1995). In the study by Mutter et al (Lagarda, Catasus 
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et al. 2001), the authors reported k-RAS mutations in 18.9% of 58 endometrial cancers, all of 
them were of endometrioid type. They also described a higher frequency of k-RAS 
mutations in MSI (+) carcinomas (6 of 14, 42.8%) than in MSI (-) tumors (5 of 44, 11.3%), 
which lead to the assumption that k-RAS mutations are common in endometrial cancer with 
the microsatellite mutator phenotype. In the same series, k-RAS mutations were detected in 
only one of 22 endometrial hyperplasia cases. In this case, atypical hyperplasia coexisted 
with carcinoma; interestingly, both lesions exhibited MLH-1 promoter hypermethylation, 
MSI, and identical PTEN mutations, but they had different k-RAS mutations; of the 
remaining 21 endometrial hyperplasias, 6 had shown MLH-1 promoter hypermethylation 
and one had both MLH 1 methylation and MSI. Accordingly, the authors hypothesized that 
“both k-RAS and MSI are closely related phenomena that may occur simultaneously before 
and during clonal expansion”. 
Microsatelite instability (MSI) 
Among sporadic type I endometrial cancer of all grades, approximately 20% demonstrate a 
molecular phenotype referred to as Microsatelite instability (MSI) (Risinger, Berchuck et al. 
1993; Burks, Kessis et al. 1994; Duggan, Felix et al. 1994; Mutter, Boynton et al. 1996). MSI is 
rare (< 5%) in type II endometrial cancer (Faquin, Fitzgerald et al. 2000; Goodfellow, Buttin et al. 
2003). Microsatellites are short segments of repetitive DNA bases that are scattered throughout 
the genome; they are found predominantly in noncoding DNA. Due to DNA repair errors 
made during replication, the tendency to develop changes in the number of repeat elements as 
compared with normal tissue is termed MSI. MLH1 inactivation, a component of the mismatch 
repair system, is the most common mechanism in endometrial carcinoma and is accomplished 
by hypermethylation of CpG islands in the gene promoter, a process known as epigenetic 
silencing.(Esteller, Levine et al. 1998) Inherited or somatically acquired mutations of MSH6, 
another mismatch repair element, are also common in patients with MSI endometrial 
cancers.(Goodfellow, Buttin et al. 2003) MSI in general, and abnormal methylation of MLH1 in 
particular, is an early event in endometrial carcinogenesis that has been described in 
precancerous lesions (Mutter, Boynton et al. 1996; Levine, Cargile et al. 1998; Esteller, Catasus 
et al. 1999). The significance of MSI may also be a result of its ability to specifically inactivate 
other genes which contain susceptible repeat elements, such as transforming growth factor 
receptor type II, (TGF-âRII), BAX, insulin-like growth factor II receptor (IGFIIR), and hMSH3, 
resulting in secondary tumor sub-clones with an increased capacity to invade and metastasize 
(Ouyang, Shiwaku et al. 1997; Catasus, Matias-Guiu et al. 2000). 
p53 
p53 is a nuclear phosphoprotein that provoke cell cycle arrest or apoptosis through 
induction of P21Waf1/Cip1 and hMdm2 in response to cellular stress (Hecht and Mutter 
2006). Mutations involving p53 are among the most commonly encountered molecular 
abnormalities in type II endometrial cancer (detailed in subsequent sections), and are usually 
due to p53 truncation mutations (Alkushi, Lim et al. 2004). On the other hand, only 5% of 
type I endometrial cancers show aberrant accumulation of inactivated p53 protein (Lax, 
Kendall et al. 2000), may be secondary to changes in its upstream regulatory proteins 
(Soslow, Shen et al. 1998) rather than truncation mutations. Examples of such upstream 
regulatory molecules include MDM2 and p14 ARF, that regulate p53 levels and their 
dysregulation had been shown to cause detectable levels of p53 in the absence of p53 
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mutation,  and may be associated with adverse clinical outcomes(Soslow, Shen et al. 1998; 
Schmitz, Hendricks et al. 2000; Pijnenborg, van de Broek et al. 2006). p53 overexpression and 
high protein levels are thought to be associated with high grade and stage, but is also an 
independent prognostic factor (Alkushi, Lim et al. 2004). Other possible causes for p53 
accumulation in type I endometrial cancers may be nonspecific DNA damage such as that 
induced by irradiation which is known to induce accumulation of wild-type p53 
(MacCallum and Hupp 1999).  
3. Precancers of type II endometrial cancer  
3.1 Precursor of endometrial serous carcinoma 
3.1.1 Historical backgrounds 
Endometrial carcinoma with papillary features and psammoma bodies had been described in 
the literature as early as 1960s (Karpas and Bridge 1963; Hameed and Morgan 1972; Factor 
1974). Nevertheless, the concept of “serous” differentiation and the distinguished aggressive 
behavior of such cancers were recognized 2 decades later by Lauchlan in 1981 (Lauchlan 1981), 
and shortly followed by Kempson and Hendrickson (Hendrickson, Ross et al. 1982). These 
concepts were further established by subsequent studies and case series focusing on 
morphologic features and patient survival relative to type I endometrial cancer (Lauchlan 1981; 
Eifel, Ross et al. 1983; Sherman, Bitterman et al. 1992). In 1992, Sherman et al illustrated 32 
cases of endometrial cancer with a serous component (13 pure and 19 mixed histotypes), the 
author noted the presence of “cytologically malignant cells closely resembling the invasive 
serous carcinoma in the surface endometrium adjacent to the tumor” in 28 out of the 32 
studied cases, and were entitled “intraepithelial carcinoma” (Sherman, Bitterman et al. 1992). 
Spiegel et al described a similar lesion in 1995,and designated it as “endometrial carcinoma in-
situ” (Spiegel 1995).Within the same year, Ambros et al introduced the designationof 
endometrial intraepithelial carcinoma (EIC), as a lesion that was  repeatedly and distinctively 
associated with endometrial carcinoma with a serous differentiation (Ambros, Sherman et al. 
1995). Main histologic patterns illustrated in Figure 7. 
 
Fig. 7. Morphology of endometrial serous carcinoma. Papillary pattern (A) and glandular 
pattern (B).  
However, in 1998, Zheng et al used the designation “uterine surface carcinoma” instead to 
describe that lesion, with emphasis on the multicentricity and relatively worse behavior in 
comparison to carcinoma in-situ per se, questioning the appropriateness of such a lesion as a 
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precancer (Zheng, Khurana et al. 1998). A similar approach had been published in 2000 by 
Wheeler et al, who proposed the term “minimal uterine serous carcinoma”, adding the size 
parameter (<1cm) to the definition of that lesion (Wheeler, Bell et al. 2000). 
3.1.2 Zheng’s model for precursors of type II endometrial cancer 
Serous EIC is still used in the most recent (2003)WHO classification as the precancerous 
lesion for serous endometrial carcinoma (Tavassoli FA 2003). However, in our opinion, the 
fact that stage 1A non-myoinvasive serous carcinomas are known to display extrauterine 
disease in 17-67% of studied cases (Carcangiu, Tan et al. 1997; Gehrig, Groben et al. 2001; 
Zheng and Schwartz 2005), strongly argues against the designation of serous EIC as a true 
“precancer”. Many years of gynecological surgical experience and studies of patient 
outcome have show that many patients diagnosed with serous EIC and treated with simple 
hysterectomy without surgical staging, had recurrences or intra-abdominal carcinomatosis 
(Carcangiu, Tan et al. 1997; Gehrig, Groben et al. 2001; Chan, Loizzi et al. 2003; Zheng and 
Schwartz 2005). Consequently, serous EIC is better recognized as an endometrial serous  
carcinoma with an early, non-myoinvasive growth pattern (Zheng and Schwartz 2005).  
Careful examination of the definition of a precancer established in the National Cancer 
Institute Consensus in 2006, resulted in the conclusion that EmGD fulfills most of the defined 
criteria as a precancer of Type II endometrial cancer. The diagnostic criteria of serous EmGD 
were established by Zheng et al in 2004 (Zheng, Liang et al. 2004). Using morphological as well 
as immunohistochemical features, the EmGD lesions display changes that bridge the gap 
between benign endometrium and frankly malignant epithelium of serous EIC ( Figure 8); the 
dysplastic epithelium of EmGD has cytologic features that are more atypical than resting 
endometrium but fall short of serous EIC (Figure 9), as discussed in Table 3. 
Macroscopic features 
Grossly, no visible lesions could be identified in the corresponding areas of EmGD (Zheng, 
Liang et al. 2004). 
 
Fig. 8. Proposed model for endometrial serous carcinogenesis by Zheng et al (Zheng, Xiang 
et al. 2011). 
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3.1.3 Diagnostic criteria of serous EmGD 
Serous EmGD 
Criterion 
Comments 
Patient age Postmenopausal women, classically elder than 55 years old 
Architecture & 
Cytology 
Atypical endometrial glandular epithelium. The degree of 
atypia falls short of serous EIC. Many in endometrial polyp 
Size limit and 
background 
No size limit. Background is often atrophic or weakly 
proliferative, could be proliferative and rarely hyperplastic. 
Exclude mimics Benign conditions with overlapping features: bleeding or 
curettage associated atypia, repair, polyp with metaplastic 
changes 
Exclude cancer Serous EIC has frankly malignant cells same as in ESC/UPSC 
Table 3. Serous EIN (serous EmGD) fact sheet 
Microscopic features 
The EmGD lesions are frequently multifocal (86% of cases) (Fadare and Zheng 2008). 
Classically, EmGD is characterized by glands and/or surface endometrial epithelium with 
atypical cytologic features. The cells of EmGD shows oval or round nuclei with a 2-3 folds 
nuclear enlargement compared with the benign resting endometrium. The nuclei are either 
hyperchromatic or with open chromatin patterns. When hyperchromasia is present, the 
degree of hyperchromasia is less than that of frankly malignant cells seen in serous EIC. 
Nucleoli are usually conspicuous instead of prominent. Partial loss of cell polarity is seen 
when nuclear stratification is present. A few stratifications may be seen. Mitotic figures and 
apoptotic bodies are appreciable, but not easily identified. Small papillary structures can be 
identified in  EmGD glands, the thin fibrovascular cores of the EmGD papillae are also lined 
by dysplastic cells instead of malignant cells as in serous EIC or ESC. Occasional mitotic 
figures are present, but no abnormal mitoses are seen in EmGD lesions. Apoptotic bodies 
are scarce and in one of our series ranged from 0 to 5 per gland with an average of 1.5/gland 
(Zheng, Liang et al. 2004). The most common microscopic patterns include glandular 
involvement, either as a single or a group of EmGD glands within the endometrium or 
within an endometrial polyp. Another pattern is surface epithelial involvment of the 
endometrium or lining a polyp. EmGD foci are usually smaller than 1 mm in size. This may 
be related to the fact that they often presented as a single or a group of a few glands. 
However, occasionally, potential serous EmGD glands form clusters. When in endometrial 
polyps, the overall size of serous EmGD lesions may reach several millimeters. The stroma 
around the serous EmGD glands is usually fibrotic, but desmoplastic reactions are not seen. 
Background endometrium is often atrophic or weakly proliferative endometrium, but it 
could also be proliferative or rarely hyperplastic. This is actually a significant point to keep 
in mind, since nowadays; a considerable number of post-menopausal women are using 
hormonal replacement therapy compared to those who did 2 or 3 decades ago. In clinical 
practice, this is translated to the fact that about 40% of women with serous EIC or ESC have 
a non-atrophic endometrium as a background (Zheng, Liang et al. 2004) (34% proliferative, 
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6% hyperplastic endometrium). The significance of these findings is, in one hand, it 
provides further evidence that hormones are not risk factors for type II endometrial cancer; 
and on the other hand, pathologists should keep endometrial serous carcinoma as a 
differential diagnosis even in the existence of endometrial hyperplasia, in order to avoid the 
misdiagnosis of type I endometrial cancer, and the substantial consequences on patient 
management and outcome. 
 
Fig. 9. Endometrial glandular dysplasia ( EmGD) morphology. EmGD bridges the 
morphologic gap between benign resting endometrium (RE) and endometrial intraepithelial 
carcinoma (EIC).  
 
Fig. 10. p53 immunohistochemical stain in EmGD lesions. EmGD may involve the surface 
epithelium (upper left) or endometrial glands (lower left). The right panel shows diffuse 
nuclear positivity for p53 stain in areas corresponding to those in the left panel. 
3.1.4 Molecular alterations of serous EIN 
p53 Mutations. The p53 tumor suppressor gene, located on chromosome 17p 13.1, is 
probably the most commonly altered gene in human cancers (Harris 1993; Pietsch, Sykes et 
al. 2008), with the mutations commonly resulting in p53 protein over-expression 
(Darvishian, Hummer et al. 2004; Liang, Chambers et al. 2004; Jia, Liu et al. 2008). An 
extremely high rate of p53 alteration and over-expression (90% of our studied cases) had 
been detected in endometrial serous carcinoma, as evaluated by immunohistochemical 
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staining (Figure 10) (Zheng, Cao et al. 1996; Zheng, Khurana et al. 1998). In 2008, our group 
studied the frequency of TP53 gene mutations in exons 5 and 8 from laser-captured 
microdissected endometrial samples (Jia, Liu et al. 2008). In that specific context, the TP53 
gene mutations had shown a successive increment from p53 signature glands (42%) to 
EmGD (43%), to serous EIC (63 to 72%), and to ESC (96%) (Jia, Liu et al. 2008). The benign 
endometria from the control group, in contrast, showed no mutation in non-signature 
glands. Analogous findings were found in a later study by Zhang et al in 2009 (Zhang, Liang 
et al. 2009). It is concluded that p53 gene mutation is a critical and early step in endometrial 
serous carcinogenesis, and that p53 is an important diagnostic immunohistochemical tool in 
this situation (Liang, Chambers et al. 2004; Jia, Liu et al. 2008; Zheng, Xiang et al. 2011). 
BRCA Mutations 
A subset of relatively younger women with hereditary breast cancers are also at increased 
risk for the development of subsequent ovarian/tubal serous malignancies as a 
manifestation of hereditary breast-ovarian syndrome (Hall, Jamison et al. 2001; Arai, 
Utsunomiya et al. 2004), and in patients with BRCA mutations (Lavie, Hornreich et al. 2004). 
An earlier paper by Curtis et al in 1973, had described other malignancies that may follow 
breast cancer, including endometrial cancer (Inskip and Curtis 2007). The exact nature of 
this link between breast and endometrial cancer is still unclear; however, a few foundational 
studies had shed some light on evidences for such a relationship. In 1999, Hornreich et al 
reported a case of “uterine serous papillary carcinoma” in 2 siblings with both endometrial 
and ovarian serous carcinomas who were carrying identical mutation in BRCA1 gene 
(Hornreich, Beller et al. 1999). Genetic analysis showed loss of the wild-type allele, 
suggesting a link between germline BRCA1 mutation and serous cancer. A following study 
of Ashkenazi Jewish patients with endometrial serous carcinoma confirmed a high incidence 
of BRCA1 mutation and LOH (75% of tumor samples) (Lavie, Hornreich et al. 2004). A 
contradictory result was found in a study by the same group on a population of germline-
BRCA mutation carriers, showing no relationship to increased risk of endometrial cancer. 
Another disagreement was reported by Liu et al, who found no significant increase in 
BRCA1 mutation in sporadic endometrial cancers  (Liu, Ho et al. 1997). 
Based on epidemiologic data, Chan et al had reported an association between breast cancer 
and endometrial cancers with aggressive histological types (Chan, Manuel et al. 2006). In 
2007, a Swedish study found that 7.28% of patients undergoing genetic counseling for an 
increased risk of breast cancer, had family histories of both endometrial and breast cancers 
(von Wachenfeldt, Lindblom et al. 2007). We recently published a large cohort study that 
had found a history of a prior breast cancer in 20% of women with ESC, with the incidence 
being significantly higher in patients who were 55 years old or younger (41.5%) in 
comparison to those older than 55 years (16%) (Liang, Pearl et al. 2010).  
In the light of the current controversy, further studies are absolutely needed to clarify the 
possible role of BRCA mutations in ESC. Contemporary data regarding BRCA mutations in 
serous EIC and EmGD lesions are still lacking. 
Alteration of extracellular adhesion molecules 
Studies of the role of extracellular adhesion molecules in the development of ESC are 
limited relative to studies of tumor supressor genes and oncogens. As aforementioned, ESC 
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has the unusual capacity to metastasize outside the uterus even in the absence of 
myometrial invasion. This might be linked to alterations of the extracellular adhesion 
molecules of the neoplastic serous epithelium. Such alterations likely assist the transtubal 
spread of ESC into the peritoneum, and consequently result in the advanced stage of disease 
at time of diagnosis, even with limited uterine disease. The phenomenon of transtubal 
spread of serous carcinoma cells had been emphasized by our study of serous EIC lesions in 
2005 (Zheng and Schwartz 2005). In that study, 67% (6 out of 9) serous EIC cases had 
peritoneal carcinomatosis, and among these cases, 50% showed free-floating serous 
malignant cells and cell clusters in the tubal lumena (Zheng and Schwartz 2005). Our 
suggestion was further supported by the former findings of identical clones of cells in 
serous EIC and serous carcinomas at extrauterine sites (Kupryjanczyk, Thor et al. 1996; 
Baergen, Warren et al. 2001). 
Of these extracellular molecules, E-cadherin and claudins had been described as potential 
contributors to the biological aggressiveness of ESC. E-cadherin downregulation had been 
previously reported to be associated with the progression of endometrial cancers (Sakuragi, 
Nishiya et al. 1994; Holcomb, Delatorre et al. 2002; Mell, Meyer et al. 2004). Holocomb et al 
described a reduction of E-cadherin expression in 62% and 87% of their studied serous 
carcinoma and clear cell carcinoma, respectively (Holcomb, Delatorre et al. 2002). A recent 
study showed that loss of E-cadherin may be attributed to L1CAM upregulation in the 
aggressive subtype of endometrial cancer (Huszar, Pfeifer et al.). Claudins are a family of 
extracellular tight junction proteins that are said to be up regulated in ovarian cancers (Rangel, 
Agarwal et al. 2003), and possibly related to cancer progression (Santin, Bellone et al. 2007). 
Expression of claudins, especially claudin-3 and claudin-4, is also higher in type II endometrial 
cancers relative to type I endometrial cancers (Konecny, Agarwal et al. 2008). CD44 is a protein 
involved in cell adhesion and leukocyte homing, CD44v6 is one of its isoforms that may be 
related to lymphovascular space invasion and metastasis. A significant loss of CD44 and that 
particular isoform CD44v6 had been detected in ESC compared to EEC (Soslow, Shen et al. 
1998). β-catenin is a transcriptional activator downstream of the Wnt signaling pathway. Many 
types of human cancers harbor mutations of β-catenin, including endometrial cancers. 
Fukuchi et al (Fukuchi, Sakamoto et al. 1998)detected B-catenin mutations in 13% (10 out of 76) 
of their ESC cases. Whether or not serous EmGD show such alterations of extracellular 
adhesion molecules is still unclear and is the subject of future studies. 
Amplification of HER2/neu 
HER2/neu, also known as c-erb B2, is a protoncogen that encodes the human epidermal 
growth factor receptor  (Gehrig, Groben et al. 2001). Amplification of HER2/neu and the 
overexpression of its protein had been shown in many human malignancies, including ESC 
(Santin, Bellone et al. 2002; Casalini, Iorio et al. 2004), some studies even described that in 
association with advanced stage and poor prognosis in ESC (Santin, Bellone et al. 2002; 
Villella, Cohen et al. 2006). Although similar overexpression of HER2/neu by 
immunohistochemistry had been shown by the authors in serous EmGD and serous EIC in 
the studied cases, no data regarding the gene amplification is available so far. 
Overexpression of IMP-3 
Insulin-like growth factor m-RNA binding protein 3, or IMP-3 is a protoncogen expressed 
predominantly in embryonic tissues and rarely in adult tissues except for the placenta and 
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gonads (Nielsen, Christiansen et al. 1999; Yaniv and Yisraeli 2002). Some studies  have 
revealed that IMP-3 is associated with cell migration and tumor invasion (Yaniv and Yisraeli 
2002; Vikesaa, Hansen et al. 2006), and it could predict metastasis and prognosis in renal cell 
carcinoma(Jiang, Chu et al. 2006). In 2008, our group studied the expression of this oncofetal 
protein in serous endometrial carcinoma and its proposed precursor lesions using 
immunohistochemical staining (Zheng, Yi et al. 2008), we found that IMP-3 was 
overexpressed in 14% (3 of 21) EmGD lesions, 89% (16 of 18) serous EIC, and 94% (48 of 51) 
ESC cases. This was significantly higher than the expression detected in only 5 out of 70 
(7%) EEC cases, and was not identified in its precancer lesion (EIN) (0 of 35 cases). These 
findings imply that IMP-3 overexpression may contribute in the early steps of ESC 
development and aggressive behavior (Zheng, Yi et al. 2008). 
Overexpression of Nrf2 
NF-E2-related factor 2, or for simplicity, Nrf2, is a newly described transcription factor that 
is thought to boost the chemo-resistance of cancer cells (Wang, Sun et al. 2008). Nrf2 has 
been the subject of multiple studies by our group. In one of these studies in 2010 (Jiang, 
Chen et al.), Nrf2 showed high expression in 89% (41 of 46) of ESC cases, compared to 
marginal expression of Nrf2 in 28% (14 of 51) of EEC cases, while none of the studied benign 
endometria showed such an expression (0 of 20). Transient silencing of endogenous  Nrf2 
enhanced the sensitivity to chemotherputic agents in SPEC-2 cells derived from ESC (Zheng, 
Xiang et al. 2011). In addition, Overexpression of Keap1, a negative regulatory gene of Nrf2, 
significantly sensitized those ESC-derived SPEC-2 cells and its xenografts to 
chemotherapeutic drugs. More recently, we have also examined Nrf2 expression in 
precursor lesions of ESC, and found that Nrf2 was expressed in 40% of EmGD lesions, and 
44% of serous EIC lesions in the studied cases (Chen, Yi et al.); it also showed a lesser degree 
of expression in clear cell carcinoma (13%) and its proposed precursor lesions, clear cell 
EmGD and EIC (10% and 25%), respectively. In the same study, only 6% of EEC (3 out of 50) 
and none of the atypical endometrial hyperplasia/EIN showed overexpression of Nrf2 
(Chen, Yi et al.). The relationship between Nrf2 and early steps of ESC carcinogenesis and 
p53 mutations is currently under exploration in our laboratory. 
Overexpression of p16 
p16, also known as CDKN2A, is a tumor supressor gene that had been extensively studied 
in the context of HPV-related cancers and their precursors (Keating, Cviko et al. 2001; 
Keating, Ince et al. 2001; Negri, Egarter-Vigl et al. 2003). In cervical HPV-related cancers, the 
mechanism of p16 overexpression may be mediated by HPV E7 viral protein. More recently, 
p16 has been also shown to be overexpressed in the cells of ESC in multiple studies (Reid-
Nicholson, Iyengar et al. 2006; Chiesa-Vottero, Malpica et al. 2007; Yemelyanova, Ji et al. 
2009). The mechanism of this overexpression, however, is probably different from that 
described in viral- related malignancies, since HPV DNA in situ hybridization has been 
negative in all studied cases (Chiesa-Vottero, Malpica et al. 2007). ESC, it is rather linked to 
the inactivation of RB gene through dysregulation of the p16INK4a/cyclin D-CDK/pRb-E2F 
pathway (Reid-Nicholson, Iyengar et al. 2006). Reid- Nicholson et al, (Reid-Nicholson, 
Iyengar et al. 2006) reported that p16 overexpression was detected in 92% (22 of 24) of ESC 
cases, compared with 7% (3 of 42) FIGO grade 1and 2 EEC, and 25% (10 of 40) of FIGO grade 
3 EEC cases. Unpublished data from our laboratory also show p16 overexpression in lesions 
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of EmGD and serous EIC (Zheng w et al, unpublished), however, it was also diffusely 
present in benign endometrial samples, raising the question of the practical relevance of this 
biomarker in serous carcinogenesis. 
3.1.5 Differential diagnosis  
The diagnosis of serous EIN can be difficult because it does not present as a mass. It may be 
a focal finding in an otherwise unremarkable endometrial polyp. This is particularly true 
when a biopsy sample is encountered. The overall clinico-pathologic picture is significant to 
avoid misdiagnosis (Table 3). The recognition of serous EmGD in an endometrial biopsy or a 
curettage specimen may aid the pathologist to diagnose serous EIC or to raise concerns for 
the presence of concurrent ESC before a hysterectomy is undertaken. Attention should be 
paid in the interpretation of endometrial specimens not to confuse EmGD with any of the 
following pathologic entities: 
Reparative epithelial changes in benign endometrium 
These benign changes are frequently encountered post –endometrial curettage or biopsy and 
rarely show the architectural patterns seen in EmGD. The cytologic atypia is minimal. 
Numerous mitotic figures are lacking as well. In difficult cases, the use of 
immunohistochemical stains for p53, IMP-3 and ki-67 can be very useful (Figure 11 A &11B). 
Serous EIC 
The most useful criterion here is nuclear atypia, which is marked in serous EIC, even 
identical to that of invasive ESC. Mitotic figures are also more frequent in EIC. 
Benign endometrial metaplasias 
These may include hobnail metaplasia, papillary metaplasia and also some cases of Arias-
Stella reaction. The cytologic atypia in these various types of metaplasia are minimal and 
they are usually associated with bleeding or breakdown changes in adjacent endometrium. 
Mitotic activity is rarely seen. Other characteristic cytologic features, such as hobnail nuclei 
  
Fig. 11. Reactive endometrial changes. Post-abortive decidulized endometrium may show 
atypical glandular cells (A), but immunostaining with p53 is weak and focal (B). Hobnail 
metaplasia in endometrial curretings (C), lack of mitoses and negative p53 stain (D) helps to 
rule out malignancy. 
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or cytoplasmic clearing or eosinophilia can further help in the distinction. Pathologic 
examination should always keep pace with the clinical data and presentation, as a history of 
a preceeding conception or dilation and curettage will help minimize the misdiagnosis of 
such benign changes with serous EmGD. An example is illustrated in Figure 11C & 11D. 
Endometrial hyperplasia 
As previously mentioned, it is of clinical significance to accurately differentiate between the 
precursors of type I and type II endometrial cancer, due to the influence on management and 
patient outcome. In most of the cases, this should be straightforward, bearing in mind that 
type I endometrial cancer precursors usually lack the highly atypical nuclear features seen in 
type II precancers, including hobnail appearance, round large nuclei and prominent 
nucleoli. However, in case of doubt, correlation with positive immunohistochemical stains 
for p53, IMP-3 would help diagnose type II endometrial cancer precancers. 
3.1.6 Clinical significance and future management 
At present, there are no standard management guidelines for patients with EmGD. The 
approach at our institute is based on our consideration of these patients to be at a 
significantly higher risk for the development of endometrial malignancy than their 
counterparts without EmGD, and that this risk is accentuated by factors such as a personal 
history of breast cancer or BRCA mutations(Chan, Manuel et al. 2006; Liang, Pearl et al. 
2010). For patients without breast cancer history and/or BRCA mutations, if the diagnosis of 
EmGD is confirmed in a biopsy, we recommend complete dilation and curettage (D&C) for 
larger sampling. If the diagnosis was made on an endometrial curettage, we recommend 
periodic follow-up (no more than every 6 months) with transvaginal ultrasound and pelvic 
examinations. The presence of any abnormalities during this period that may be a harbinger 
for neoplasia, such as persistent abnormal uterine bleeding, abnormal glandular cells on 
Papanicolaou tests, palpable pelvic masses, or ultrasound abnormalities, should warrant a 
complete D and C. For those patients with BRCA mutations or a personal history of breast 
cancer, our gynecologic oncologists typically offer the option for a hysterectomy. Whether or 
not complete staging is performed would then be dependent on the intraoperative frozen 
section findings. If a serous cancer is identified, irrespective of its size in representative 
sections of the uterus, a complete staging, including omentectomy is performed. If no such 
focus is identified, the procedure is limited to the hysterectomy with or without the 
salpingoophorectomies. It should be emphasized, however, that additional studies are 
required to more clearly define the clinical significance of the lesion in everyday practice. 
This would entail a larger systematic study of endometrial biopsies to establish the time 
frame between the development of EmGD and ESC, the proportion of EmGD cases that 
evolve to ESC, and follow-up of prospectively diagnosed cases to confirm that they are 
never associated with extrauterine disease in a short term. 
3.2 Clear cell EmGD 
3.2.1 Historical background 
Endometrial clear cell carcinoma (ECCC) is a rare variant of endometrial type II cancer, 
accounting for 1% to 6% of all endometrial carcinomas cases (Webb and Lagios 1987; Abeler 
and Kjorstad 1991). It is now established that precursor lesions exist for the more common 
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and more thoroughly studied types of endometrial cancers, including the spectrum of 
atypical hyperplasia and classic (endometrioid) EIN for type I endometrial cancer (Kurman, 
Kaminski et al. 1985; Mutter 2000; Mutter 2002; Mutter, Zaino et al. 2007; Scully RE 1994); 
and serous endometrial glandular dysplasia (EmGD) for ESC (Zheng, Liang et al. 2004; 
Zheng, Liang et al. 2007; Fadare and Zheng 2009; Zheng, Xiang et al. 2011). However, the 
other rarer and accordingly less studied variants of endometrial carcinoma, including 
ECCC, has not been the focus of similar searches. A few pioneer studies are mentioned in 
the following sections.  
 
Fig. 12. Clear cell carcinoma of the endometrium. 
3.2.2 Putative precursor for endometrial clear cell carcinoma: Clear cell EmGD 
In 2004, Moid and Berezowski (Moid and Berezowski 2004) described a distinctive lesion in 
a hysterectomy specimen from a 70-year-old woman which they designated endometrial 
intraepithelial carcinoma, clear cell type (EIC, clear cell type). The lesion comprised surface 
epithelium and glands that were lined by cells with ‘‘clear cytoplasm, marked nuclear 
pleomorphism, coarse chromatin, irregular nuclear membranes, and prominent eosinophilic 
nucleoli’’ and an occasional hobnail appearance. No mitotic figures were recognized. There 
was no evidence of stromal or myometrial invasion. The lesions showed ‘‘focal’’ staining for 
p53, a ‘‘moderate to high proliferative index,’’ and no evidence of extrauterine extension. In 
2006, our group studied the characteristic clinicopathologic features of these putative 
precursor lesions (Fadare, Liang et al. 2006). 14 cases of pure ECCC and 16 endometrial 
carcinomas with a greater than 10% clear cell component were evaluated, the adjacent 
benign endometria were searched for lesions that were morphologically distinct from the 
background benign endometrium and which were not clearly classifiable as a non-
neoplastic process. A total of 38 benign uteri and 30 uteri with EEC served as the control 
groups. In 90% of cases, we identified a spectrum of atypical endometrial glandular and 
surface changes that were distinct from both the background benign endometrium and the 
adjacent ECCC. These changes were not identified in any of the control group cases. 
Transition from resting endometrium to clear cell EmGD, or from clear cell EmGD to clear 
cell EIC, was detected in 11 (41%) of 27 cases(Fadare, Liang et al. 2006). These morphological 
changes were also maintained by immunohistochemical stains, which showed that the clear 
cell EmGD lesions had p53 staining scores and MIB1 proliferative indices that were 
intermediate between the resting endometrium in which they were identified and the 
adjacent ECCC. The lesions also showed markedly reduced frequency of ER and PR 
expression compared with the background endometrium. According to our findings, we 
hypothesized that these lesions represent precancerous lesions of ECCC. There has been an 
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inadequate number of cases described to know if clear cell EIC in isolation, like serous EIC, 
has any capacity or propensity for extrauterine extension. Additional studies, as have 
previously been carried out on serous EmGD(Zheng, Liang et al. 2007; Zheng, Xiang et al. 
2011), are required to conclusively establish the precancerous nature of these per National 
Cancer Institute criteria(Berman, Albores-Saavedra et al. 2006). 
3.2.3 Morphologic features of clear cell EmGD 
The features of clear cell EmGD are a spectrum of morphological changes involving a single 
gland, a few glandular clusters or surface epithelium lined by cells with cytoplasmic clarity 
or eosinophilia, or hobnail nuclei, and varying degrees of nuclear atypia. These changes 
were graded on a scale of 1 to 3 (Fadare, Liang et al. 2006), primarily depending on the level 
of cytologic atypia of the constituent cells. A lesion is grade 1 if there is nuclear enlargement 
(2- to 3-fold compared with resting endometrium) (Figure 13). Grade 3 nuclei show marked 
pleomorphism and prominent nucleoli comparable to frank ECCC (Figure 12). Grade 2 
changes display intermediate features. Mitotic figures were rare in grade 1 and 2 lesions but 
were easily seen in grade 3 lesions. Morphologically and conceptually, grade 3 lesions were 
classifiable as clear cell EIC, whereas grade 1 and 2 lesions were designated clear cell 
endometrial glandular dysplasia (clear cell EmGD). 
3.2.4 Molecular alterations of clear cell EmGD 
The genetic aspects of ECCC are not fully understood, and further studies are required to 
establish the exact pathogenesis of this unusual tumor. The information assembled from 
previous efforts suggests that the molecular pathogenesis of ECCC is different from that of 
EEC and ESC, and that the molecular alterations frequently detected in EEC and ESC, 
including PTEN, K-ras, and TP53 mutations, are not commonly seen in ECCC. Lax et al 
(Lax, Pizer et al. 1998); noted that a division of ECCC cases display morphologic features 
suggestive of ESC (ECCC with serous features) and that the latter showed a higher Ki-67 
proliferative index than did typical ECCC. Furthermore, ECCC with serous features were 
associated with serous endometrial intraepithelial carcinoma (EIC) in 50% of cases. In 2004, 
An et al (An, Logani et al. 2004), studied 16 ECCCs (including 11 pure and 5 mixed cases) for 
mutations in the PTEN and p53 genes, and for microsatellite instability. These alterations 
were detected in only a minority of the pure cases, but they were present in the mixed 
tumors. In addition, in the 2 cases of mixed ECCC/ESC, identical p53 mutations were 
identified in the 2 histologically distinct parts of the tumor. In one case of a mixed 
ECCC/EEC, identical p53 and PTEN mutations, as well as microsatellite instability, were 
identified in the 2 components. The authors concluded that ECCC ‘‘represent a 
heterogeneous group of tumors that arise via different pathogenetic pathways.’’  
As previously noted, molecular alterations that are characteristic of ESC, such as p53 
mutations or down-regulation of E-cadherin, may also be seen in ECCC but at a significantly 
lower frequency  (Lax, Pizer et al. 1998; Holcomb, Delatorre et al. 2002; Yalta, Atay et al. 
2009). On the other hand, expression of ER and PR is seen at a considerably lower rate in 
ECCC than is typical of EEC. Other alterations that have been reported in ECCC include 
decreased expression of the metastasis suppressor CD82 (Kangai-1) and frequent 
hypermethylation of the stem cell-related transcription factor (SOX2), and up-regulation of  
www.intechopen.com
 Intraepithelial Neoplasia 
 
230 
the oncogenesis-related protein HNF-1A. The first 2 of these alterations are considered to be 
linked to type II cancers in general, rather than ECCC in particular(Wong, Huo et al.). The 
precise molecular alterations in clear cell EmGD and clear cell EIC are still uncertain and 
further molecular and genetic studies are necessary to elucidate them. 
 
Fig. 13. Clear cell endometrial glandular dysplasia (clear cell EmGD). It can be seen in the 
surface epithelium (A), or single glands (C&D). Imunohistochemical stain  
for p53 is positive (B).  
3.2.5 Clinical significance and future management  
Due to limited number of clear cell EmGD cases that have been studied,the practical clinical 
impact of this diagnosis, especially if it is found in isolation in an endometrial biopsy 
sample, is simply unclear. Guidelines on how to manage such cases will not be available 
until more retrospective and prospective studies are done. Clear cell carcinoma is a rare type 
of endometrial type II carcinoma. Studies of precursor lesions are so far scarse. We 
previously proposed clear cell EmGD as a putative precursor due to similarities in 
morphologic and immunophenotypic features of clear cell carcinoma. However, follow-up 
and molecular studies are required to establish an ancestry connection between the clear cell 
EmGD, clear cell EIC, and ECCC and to illuminate the genetic pathways involved in the 
development and progression of these putative precursor lesions. 
4. Conclusion  
Endometrial carcinomas encompass a wide spectrum of morphologically and biologically 
distinct entities. These can be categorized into 2 major pathways (type I and type II 
endometrial cancer) according to the dualistic model of endometrial carcinogenesis. Both 
types have histologic subtypes, and are distinct in their risk factors, molecular background, 
precancerous lesions and overall patient outcome. The histologic subtype of endometrial 
cancer has been demonstrated as a significant prognostic factor. The previously used 
contradicting nomenclature systems for endometrial precancers had been a basis for 
confusion and low reproducibility among pathologists. They also resulted in the 
inappropriate inclusion of certain lesions as precancer lesions that did not qualify as such 
(e.g. simple hyperplasia without atypia for type I endometrial cancer, and serous EIC for type II 
endometrial cancer); which in our opinion makes it essential to search for a more simple and 
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unified nomenclature system in this context. Based on the previously detailed dualistic 
model of endometrial carcinogenesis, and with emphasis on the strict criteria of a precancer 
as defined by the 2006 National Cancer Institute consensus; we believe that endometrioid 
EIN (as defined by Mutter et al) is the precancer lesion for type I endometrial cancer. For type II 
endometrial cancer, on the other hand, our recent studies confirmed that serous EIN (serous 
EmGD as previously defined) is the precancerous lesion for serous carcinoma. Similarly, 
clear cell EIN (previously defined as clear cell EmGD) as a putative precancer for clear cell 
carcinoma. The precancers of type I and type II endometrial cancer are morphologically and 
biologically distinct entities, and to the best of our knowledge do not overlap or function as 
precancer of their cancer counterparts. Much is still to be explored regarding the nature, 
clinical significance, and appropriate management of those precancer lesions. The newly 
proposed unified endometrial intraepithelial neoplasia classification system, hopefully, will 
reduce the confusion in clinic and ultimately benefit patients.   
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